Concepedia
Statistics
Publications
10
Citations
590
H-Index
Active since
1999
Affiliations
University of Groningen(Current)
AstraZeneca (Sweden)
Boehringer Ingelheim (Germany)
Xendo (Netherlands)
Utrecht University
Wim J. Tamminga is an author at University of Groningen specializing in pharmacology, medicine, and pharmacogenetics.
Publications per year
1999–2014
Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [<sup>14</sup>C]Telmisartan in Healthy Volunteers
Joachim Stangier, Jochen Schmid, Dietrich Türck et al. · The Journal of Clinical Pharmacology · 2000 · 146 citations
Pharmacy, Pharmacokinetics, Pharmacology +15
CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences
Wim J. Tamminga, J. Wemer, B. Oosterhuis et al. · European Journal of Clinical Pharmacology · 1999 · 144 citations
Medicine, Endocrinology, Gynecology +16
The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers
Wim J. Tamminga, J. Wemer, B. Oosterhuis et al. · European Journal of Clinical Pharmacology · 2001 · 99 citations
Life Sciences, Genetics, Pharmacology +10
Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge
Joachim Stangier, Chung‐An P. F. Su, P. N. M. van Heiningen et al. · Journal of Cardiovascular Pharmacology · 2001 · 44 citations
Medicine, Pharmacology, Pharmacotherapy +15
An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19
Wim J. Tamminga, Johan Wemer, B. Oosterhuis et al. · European Journal of Clinical Pharmacology · 2001 · 41 citations
Medicine, Genetics, Computational Phenotyping +8
1–5 of 10